Global Oncolytic Virus Manufacturing Services Market Growth (Status and Outlook) 2024-2030

Global Oncolytic Virus Manufacturing Services Market Growth (Status and Outlook) 2024-2030

Oncolytic virus manufacturing services refer to specialized biomanufacturing processes that involve the production of oncolytic viruses, which are viruses engineered or naturally occurring that selectively infect and kill cancer cells. These services encompass a range of activities, from virus design and development to large-scale production and quality control, ensuring that the oncolytic viruses are safe, effective, and meet regulatory standards for clinical and commercial use.

The global Oncolytic Virus Manufacturing Services market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Oncolytic Virus Manufacturing Services Industry Forecast” looks at past sales and reviews total world Oncolytic Virus Manufacturing Services sales in 2022, providing a comprehensive analysis by region and market sector of projected Oncolytic Virus Manufacturing Services sales for 2023 through 2029. With Oncolytic Virus Manufacturing Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oncolytic Virus Manufacturing Services industry.

This Insight Report provides a comprehensive analysis of the global Oncolytic Virus Manufacturing Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oncolytic Virus Manufacturing Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oncolytic Virus Manufacturing Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncolytic Virus Manufacturing Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncolytic Virus Manufacturing Services.

United States market for Oncolytic Virus Manufacturing Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Oncolytic Virus Manufacturing Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Oncolytic Virus Manufacturing Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Oncolytic Virus Manufacturing Services players cover Recipharm (Vibalogics), IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Oncolytic Virus Manufacturing Services market by product type, application, key players and key regions and countries.

Segmentation by Type:
Oncolytic Herpes Simplex Virus
Oncolytic Adenovirus
Oncolytic Vaccinia Virus
Others

Segmentation by Application:
R&D
Biopharmaceutical Manufacturers
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Oncolytic Herpes Simplex Virus
Oncolytic Adenovirus
Oncolytic Vaccinia Virus
Others

Segmentation by Application:
R&D
Biopharmaceutical Manufacturers
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Recipharm (Vibalogics)
IDT Biologika
FUJIFILM Diosynth Biotechnologies
Exothera
Lonza
Creative Biolabs
Takara Bio
Libentech
ABL
Nabios
Halix
Obio Technology
Porton Advanced
WuXi ATU
Genevoyager

Please note: The report will take approximately 2 business days to prepare and deliver.